Innova Captab Limited has officially announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026, following a Board Meeting held on May 7, 2026. For the quarter ended March 31, 2026 (Q4 FY26), the company reported a revenue from operations of ₹4,478.02 million, representing a marginal decrease of 0.55% from the previous quarter’s (Q3 FY26) revenue of ₹4,502.93 million. However, compared to the corresponding quarter of the previous year (Q4 FY25), which saw a revenue of ₹3,147.41 million, the current quarter’s revenue increased significantly by 42.28%. The profit after tax for the current quarter stood at ₹380.83 million, reflecting a decrease of 9.65% from the ₹421.49 million reported in the preceding quarter. On a year-on-year basis, the profit grew by 28.78% compared to ₹295.73 million in the same period last year.

Innova Captab Limited is an integrated pharmaceutical company in India with a presence across the entire value chain, including research and development, manufacturing, and marketing. The company operates in a single segment focused on drugs and pharmaceutical products. Its business comprises a contract development and manufacturing organization (CDMO) business, a domestic branded generics business, and an international generics business. During the fiscal year 2025, the company continued to expand its operations, having fully integrated Sharon Bio-Medicine Limited as a step-down subsidiary. In early 2026, the company also declared an interim dividend of ₹2 per equity share, reflecting its ongoing commitment to shareholder returns. Notably, the company maintains its primary manufacturing facilities and registered offices in Haryana and Maharashtra.